Down 50% in 1 year! What’s ahead for this Rakesh Jhunjhunwala stock?
Analysts have cut FY23 earning estimates by over 20 per cent. They see a near-term hangover in terms of margin and USFDA observations but said further downside is capped as valuations have turned reasonable after the recent correction.
